Back

Platelet reactivity and activated clotting time predict haemorrhagic site complications in patients with chronic coronary syndromes undergoing percutaneous coronary intervention

26 August 2023 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Renal failure and bleeding in PCI patients Vascular Access ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Associate Professor Bogumil Ramotowski

Grochowski Hospital, Warsaw (Poland)

4 More presentations in this session

Presentation thumbnail
Comparison of percutaneous coronary intervention versus medication in dialysis patients with coronary artery disease
Doctor E. Xie (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Impact of heart failure severity and major bleeding events after percutaneous coronary intervention on subsequent major adverse cardiac events.
Doctor S. Ikebe (Kumamoto, JP)
Abstract Slides Video
Presentation thumbnail
High bleeding risk mainly predicts non-access site bleeding events in the first month after percutaneous coronary intervention
Ms E. Woelders (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Parsimonious versus extensive score: can we simplify bleeding risk stratification after percutaneous coronary intervention without losing specificity?
Ms E. Woelders (Nijmegen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Renal failure and bleeding in PCI patients

The Event

Event poster

ESC Congress 2023

26 August 2023 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Predictors and clinical outcomes of incomplete hemostasis following transradial coronary intervention: the role of activated clotting time and procedural factors
thumbnail
Congress Session
Adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention
thumbnail
Congress Presentation
Bleeding risk stratification in patients undergoing transcatheter aortic valve replacement: enhancing VARC-HBR criteria with CT-ADP as a marker of primary hemostatic disorder

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources